JP2020522697A - 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法 - Google Patents

転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法 Download PDF

Info

Publication number
JP2020522697A
JP2020522697A JP2019566358A JP2019566358A JP2020522697A JP 2020522697 A JP2020522697 A JP 2020522697A JP 2019566358 A JP2019566358 A JP 2019566358A JP 2019566358 A JP2019566358 A JP 2019566358A JP 2020522697 A JP2020522697 A JP 2020522697A
Authority
JP
Japan
Prior art keywords
ctc
ctcs
cancer
cells
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019566358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522697A5 (https=
Inventor
ディッタモア ライアン
ディッタモア ライアン
Original Assignee
エピック サイエンシス， インコーポレイテッド
エピック サイエンシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピック サイエンシス， インコーポレイテッド, エピック サイエンシス， インコーポレイテッド filed Critical エピック サイエンシス， インコーポレイテッド
Publication of JP2020522697A publication Critical patent/JP2020522697A/ja
Publication of JP2020522697A5 publication Critical patent/JP2020522697A5/ja
Priority to JP2023086656A priority Critical patent/JP2023120213A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019566358A 2017-06-02 2018-06-01 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法 Pending JP2020522697A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023086656A JP2023120213A (ja) 2017-06-02 2023-05-26 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762514642P 2017-06-02 2017-06-02
US62/514,642 2017-06-02
US201762531725P 2017-07-12 2017-07-12
US62/531,725 2017-07-12
PCT/US2018/035581 WO2018222979A1 (en) 2017-06-02 2018-06-01 Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023086656A Division JP2023120213A (ja) 2017-06-02 2023-05-26 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法

Publications (2)

Publication Number Publication Date
JP2020522697A true JP2020522697A (ja) 2020-07-30
JP2020522697A5 JP2020522697A5 (https=) 2021-07-26

Family

ID=64455086

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566358A Pending JP2020522697A (ja) 2017-06-02 2018-06-01 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法
JP2023086656A Pending JP2023120213A (ja) 2017-06-02 2023-05-26 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023086656A Pending JP2023120213A (ja) 2017-06-02 2023-05-26 転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞特徴づけに基づく治療を検出する方法

Country Status (8)

Country Link
US (2) US20220260574A1 (https=)
EP (1) EP3631445B1 (https=)
JP (2) JP2020522697A (https=)
CN (1) CN110998318A (https=)
AU (1) AU2018275265A1 (https=)
CA (1) CA3065316A1 (https=)
IL (1) IL270974A (https=)
WO (1) WO2018222979A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022092591A (ja) * 2020-12-10 2022-06-22 国立大学法人信州大学 メラノーマ患者の治療効果を判定する方法
JP2022140145A (ja) * 2021-03-12 2022-09-26 シスメックス株式会社 分析方法および分析装置
US12437563B2 (en) 2021-03-12 2025-10-07 Sysmex Corporation Analysis method and analyzer

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020225753A2 (en) * 2019-05-06 2020-11-12 Tesaro, Inc. Methods for characterizing and treating a cancer type using cancer images
CN113826169A (zh) * 2019-05-14 2021-12-21 匹兹堡大学高等教育联邦体系 用于根据多参数细胞和亚细胞成像数据表征细胞表型多样性的系统和方法
WO2021108043A1 (en) * 2019-11-27 2021-06-03 University Of Cincinnati Assessing treatment response with estimated number of tumor cells
AU2021207312A1 (en) * 2020-01-17 2022-06-30 Universität Zürich Single cell pathology analysis of tumour samples
CN114092934A (zh) * 2020-07-31 2022-02-25 骏实生物科技(上海)有限公司 循环肿瘤细胞的分类方法
CN114594252A (zh) * 2020-12-03 2022-06-07 复旦大学附属中山医院 循环肿瘤细胞形态学特征在胃癌临床诊疗中的应用
US20240054640A1 (en) * 2020-12-15 2024-02-15 Carnegie Mellon University System, Method, and Computer Program Product for Classification of Diseases Based on Expansion Microscopic Images
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150212089A1 (en) * 2014-01-30 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies
WO2016033114A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
US20160266127A1 (en) * 2013-09-30 2016-09-15 Peter Kuhn Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
WO2016196284A1 (en) * 2015-05-29 2016-12-08 Epic Sciences, Inc. Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2920317A1 (en) * 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EA201691496A1 (ru) * 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160266127A1 (en) * 2013-09-30 2016-09-15 Peter Kuhn Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
US20150212089A1 (en) * 2014-01-30 2015-07-30 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies
WO2016033114A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
WO2016196284A1 (en) * 2015-05-29 2016-12-08 Epic Sciences, Inc. Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GEORGE LEE ET AL: "Cell Orientation Entropy(COrE)：Predicting Biochemical Recurrence from Prostate Cancer Tissue Microa", MICCAI, PARTIII, LNCS, 8151, JPN7022002257, 2013, ISSN: 0004779140 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022092591A (ja) * 2020-12-10 2022-06-22 国立大学法人信州大学 メラノーマ患者の治療効果を判定する方法
JP7836038B2 (ja) 2020-12-10 2026-03-26 国立大学法人信州大学 メラノーマ患者の治療効果を判定する方法
JP2022140145A (ja) * 2021-03-12 2022-09-26 シスメックス株式会社 分析方法および分析装置
US12437563B2 (en) 2021-03-12 2025-10-07 Sysmex Corporation Analysis method and analyzer
JP7824031B2 (ja) 2021-03-12 2026-03-04 シスメックス株式会社 分析方法および分析装置

Also Published As

Publication number Publication date
CN110998318A (zh) 2020-04-10
EP3631445A1 (en) 2020-04-08
EP3631445B1 (en) 2024-09-25
US20220260574A1 (en) 2022-08-18
EP3631445A4 (en) 2021-05-26
AU2018275265A1 (en) 2020-01-30
CA3065316A1 (en) 2018-12-06
WO2018222979A1 (en) 2018-12-06
US20250155440A1 (en) 2025-05-15
JP2023120213A (ja) 2023-08-29
IL270974A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US20220390451A1 (en) Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
US20240027458A1 (en) Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
US20250155440A1 (en) Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease
US20230033449A1 (en) Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)
US20250180564A1 (en) Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity
US20200333345A1 (en) Circulating tumor cell diagnostics for prostate cancer biomarkers
CN107250796B (zh) 用于鉴别对雄激素受体靶向疗法的抵抗性的循环肿瘤细胞诊断

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210526

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131